Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Moxetumomab pasudotox - MedImmune

Drug Profile

Moxetumomab pasudotox - MedImmune

Alternative Names: CAT-8015; GCR-8015; HA22; LUMOXITI; Lumoxiti

Latest Information Update: 03 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer AstraZeneca; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hairy cell leukaemia
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 02 Jan 2020 European Medicines Agency accepts MAA for moxetumomab pasudotox for Hairy cell leukaemia
  • 01 Jan 2020 Preregistration for Hairy cell leukaemia (Late-stage disease, Second-line therapy or greater) in European Union (IV), before January 2020
  • 01 Jan 2020 Preregistration for Hairy cell leukaemia (Late-stage disease, Second-line therapy or greater) in Norway (IV), before January 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top